Company: TBPH
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001104659-25-110382
Chunk: 10

Company: Theravance Biopharma, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 8
Chunk 10
---
.​Significant Accounting Policies​Other than revisions to the “Future Contingent Milestone and Royalty Assets” accounting policy below, there have been no material revisions in the Company’s significant accounting policies described in Note 1 to the consolidated financial statements included in its Annual Report on Form 10-K as of and for the year ended December 31, 2024.​Future Contingent Milestone and Royalty Assets​Future contingent milestone and royalty assets (“Contingent Consideration”) on the Company’s consolidated balance sheets was initially measured at fair value in July 2022 utilizing a Monte Carlo simulation model to calculate the present value of the risk-adjusted cash flows estimated to be received from the Contingent Consideration. The fair value model involved significant unobservable inputs derived using Company estimates. The Company’s estimates were based in part on external data and reflected its judgements and forecasts. The primary significant unobservable input was the estimate of forecasted TRELEGY® ELLIPTA (“TRELEGY”) net revenues which is considered a Level 3 fair value input. ​